The CDK4/6 inhibitor, palbociclib, in combination with PARP inhibitors, added to endocrine therapy, suppresses the DNA damage repair to treat BRCA-mutated ER+ (estrogen receptor-positive) breast cancers [325]. Here, PARP1 is linked to breast cancer.